Biogen Idec Inc.: PharmaVitae Profile

Introduction
This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits
Gain insight into Biogen Idec's strategic outlook across the next 6 years
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Biogen Idec over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered
Benchmark Biogen Idec's performance against key rivals in the prescription pharmaceutical sector
See how the launch of company's multiple sclerosis portfolio is in transition as oral treatments become available

[Studien Infos ausblenden]

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003–15 6
Financial performance, 2003–15 7
Biogen Idec: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 14
Chapter 3 Quarterly news update 21
Latest quarterly sales 21
Latest comment 21
Latest prescription pharma product news 25
Latest corporate news 29
Future product milestones 32
Chapter 4 Company introduction 33
Key findings 33
Background 34
M&A history 34
Current corporate structure 37
Chapter 5 Company sales 39
Key findings 39
Prescription pharmaceutical sales and growth rate analysis, 2003–15 40
Product analysis 41
Therapy area analysis 49
Geographic analysis 51
Launch/core/expiry analysis 54
Molecule type analysis 59
Externalization analysis 62
Chapter 6 Company financials 64
Key findings 64
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09 65
Operating costs and profit analysis 66
Chapter 7 Key products and competitors 71
Key findings 71
Overview 72
Central nervous system 73
Oncology 85
Appendix 88
References 88
Abbreviations 88
About Datamonitor 90
Datamonitor consulting 90
Disclaimer 92


TABLE OF TABLES
Table 1: Biogen Idec – PharmaVitae forecasts at a glance 8
Table 2: Biogen Idec quarterly sales ($m), Q408–Q409 21
Table 3: Biogen Idec future product milestones, 2010–12 32
Table 4: Biogen Idec product portfolio overview ($m), 2003–09 43
Table 5: Biogen Idec product portfolio overview ($m), 2009–15 46
Table 6: Biogen Idec prescription pharmaceutical sales by therapy area ($m), 2009–15 50
Table 7: Biogen Idec prescription pharmaceutical sales by geographic region ($m), 2009–15 53
Table 8: Biogen Idec launch portfolio overview ($m), 2009–15 55
Table 9: Biogen Idec core portfolio overview ($m), 2009–15 56
Table 10: Biogen Idec expiry portfolio overview ($m), 2009–15 57
Table 11: Biogen Idec prescription pharmaceutical sales by molecule type ($m), 2009–15 61
Table 12: Biogen Idec prescription pharmaceutical sales by source ($m), 2009–15 63
Table 13: Total Biogen Idec sales by business unit ($m), 2003–09 65
Table 14: Biogen Idec operating revenue/cost analysis ($m), 2003–09 67
Table 15: Biogen Idec operating cost ratio analysis (% of total revenues), 2003–09 68
Table 16: Biogen Idec operating cost ratio analysis (% of total revenues), 2009–15 69
Table 17: Biogen Idec operating revenue/cost analysis ($m), 2009–15 70
Table 18: Key products overview 72
Table 19: Avonex: overview 73
Table 20: Avonex: sales forecast ($m), 2008–14 74
Table 21: Tysabri: overview 77
Table 22: Tysabri: sales forecast ($m), 2009–15 78
Table 23: Panaclar: overview 81
Table 24: Panaclar: sales forecast ($m), 2009–15 82
Table 25: Rituxan royalties: overview 85
Table 26: Rituxan royalties: sales forecast ($m), 2009–15 86


TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Biogen Idec prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 6
Figure 3: Biogen Idec’s financial performance ($m), 2003–15 7
Figure 4: The Biogen–IDEC merger 10
Figure 5: Sales of Biogen Idec’s leading multiple sclerosis therapies ($m), 2002-14 11
Figure 6: Biogen Idec’s sales performance by key brands ($m), 2002-14 13
Figure 7: Biogen Idec SWOT analysis 14
Figure 8: Current corporate structure 37
Figure 9: Biogen Idec prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 40
Figure 10: Key product sales ($m), 2003–15 42
Figure 11: Biogen Idec key sales growth drivers and resistors ($m), 2003-09 44
Figure 12: Biogen Idec key sales growth drivers and resistors ($m), 2009–15 47
Figure 13: Biogen Idec prescription pharmaceutical sales by therapy area ($m), 2003–15 49
Figure 14: Biogen Idec prescription pharmaceutical sales by geographic region ($m), 2003–15 52
Figure 15: Biogen Idec launch/core/expiry configuration ($m), 2009–15 58
Figure 16: Biogen Idec prescription pharmaceutical sales by molecule type ($m), 2003–15 59
Figure 17: Biogen Idec prescription pharmaceutical sales by source ($m), 2003–15 62
Figure 18: Biogen Idec operating revenue/cost analysis ($m), 2003–15 66


[Inhaltsverzeichnis ausblenden]